Free Trial

2seventy bio (TSVT) Stock Price, News & Analysis

-0.15 (-3.30%)
(As of 05/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
398,152 shs
Average Volume
1.21 million shs
Market Capitalization
$226.16 million
P/E Ratio
Dividend Yield
Price Target

2seventy bio MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
192.2% Upside
$12.86 Price Target
Short Interest
14.59% of Float Sold Short
Dividend Strength
News Sentiment
Insider Trading
Acquiring Shares
$3.14 M Bought Last Quarter
Proj. Earnings Growth
From ($0.93) to $0.19 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.45 out of 5 stars

Medical Sector

684th out of 915 stocks

Pharmaceutical Preparations Industry

304th out of 399 stocks

TSVT stock logo

About 2seventy bio Stock (NASDAQ:TSVT)

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

TSVT Stock Price History

TSVT Stock News Headlines

Here's what Wall Street expects from 2seventy bio's earnings
2seventy bio Inc Ordinary Shares
Bristol Myers Wins FDA Nod for Abecma
See More Headlines
Receive TSVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 2seventy bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
10 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$100.39 million
Book Value
$4.04 per share


Free Float
Market Cap
$226.16 million
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

TSVT Stock Analysis - Frequently Asked Questions

Should I buy or sell 2seventy bio stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 2seventy bio in the last twelve months. There are currently 5 hold ratings, 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TSVT shares.
View TSVT analyst ratings
or view top-rated stocks.

What is 2seventy bio's stock price target for 2024?

10 Wall Street analysts have issued 1-year price targets for 2seventy bio's shares. Their TSVT share price targets range from $5.00 to $26.00. On average, they anticipate the company's stock price to reach $12.86 in the next twelve months. This suggests a possible upside of 192.2% from the stock's current price.
View analysts price targets for TSVT
or view top-rated stocks among Wall Street analysts.

How have TSVT shares performed in 2024?

2seventy bio's stock was trading at $4.27 at the beginning of the year. Since then, TSVT stock has increased by 3.0% and is now trading at $4.40.
View the best growth stocks for 2024 here

When is 2seventy bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024.
View our TSVT earnings forecast

How were 2seventy bio's earnings last quarter?

2seventy bio, Inc. (NASDAQ:TSVT) posted its earnings results on Tuesday, March, 5th. The company reported ($1.11) EPS for the quarter, topping the consensus estimate of ($1.22) by $0.11. The business had revenue of $10.68 million for the quarter, compared to the consensus estimate of $13.91 million. 2seventy bio had a negative net margin of 313.51% and a negative trailing twelve-month return on equity of 67.59%. During the same period in the prior year, the company posted ($0.60) earnings per share.

What ETFs hold 2seventy bio's stock?
Who are 2seventy bio's major shareholders?

2seventy bio's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.26%), Healthcare of Ontario Pension Plan Trust Fund (3.38%), Jacobs Levy Equity Management Inc. (0.74%), Susquehanna Fundamental Investments LLC (0.27%), Wedmont Private Capital (0.17%) and Price T Rowe Associates Inc. MD (0.06%). Insiders that own company stock include Casdin Capital, Llc, Jessica Snow, Kynam Capital Management, Lp, Nick Leschly, Nicola Heffron, Philip D Gregory and William D Baird III.
View institutional ownership trends

How do I buy shares of 2seventy bio?

Shares of TSVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TSVT) was last updated on 5/23/2024 by Staff

From Our Partners